Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.
暂无分享,去创建一个
[1] M. Covington,et al. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream , 2021, Pharmaceutics.
[2] S. Vermeire,et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial , 2021, The Lancet.
[3] P. Higgins,et al. Tofacitinib for Biologic-Experienced Hospitalized Patients with Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[4] S. Vermeire,et al. OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study , 2021, Journal of Crohn's & Colitis.
[5] S. Vermeire,et al. OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study , 2021, Journal of Crohn's & Colitis.
[6] I. McInnes,et al. Filgotinib, a Novel JAK1-Preferential Inhibitor for the Treatment of Rheumatoid Arthritis: An Overview from Clinical Trials. , 2021, Modern rheumatology.
[7] B. Sands,et al. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] S. Vermeire,et al. Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study , 2021, Zeitschrift für Gastroenterologie.
[9] V. Jairath,et al. High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF. , 2021, Inflammatory bowel diseases.
[10] D. M. van der Heijde,et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial , 2021, Annals of the Rheumatic Diseases.
[11] S. Ramamoorthy,et al. Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-based Cohorts. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] B. Haraoui,et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. , 2020, The New England journal of medicine.
[13] S. Vermeire,et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease , 2020, Nature Reviews Gastroenterology & Hepatology.
[14] P. Lefèvre,et al. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease , 2020, Journal of Crohn's & colitis.
[15] J. Leighton,et al. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme , 2020, Journal of Crohn's & colitis.
[16] P. Higgins,et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. , 2020, Gastroenterology.
[17] J. Lewis,et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. , 2020, Gastroenterology.
[18] C. J. van der Woude,et al. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. , 2020, Best practice & research. Clinical gastroenterology.
[19] Siddharth Singh,et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. , 2020, Gastroenterology.
[20] Siddharth Singh,et al. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. , 2020, Gastroenterology.
[21] S. Bonovas,et al. Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.
[22] B. Sands,et al. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[23] C. Peterfy,et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial , 2019, Arthritis & rheumatology.
[24] B. Sands,et al. Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open , 2019, Alimentary pharmacology & therapeutics.
[25] B. Sands,et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme , 2019, Alimentary pharmacology & therapeutics.
[26] A. Orbai,et al. Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives , 2019, Psoriasis.
[27] B. Sands,et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[28] B. Feagan,et al. Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease , 2019, Alimentary pharmacology & therapeutics.
[29] J. Cappelleri,et al. The Epidemiology of Herpes Zoster and Postherpetic Neuralgia in China: Results from a Cross-Sectional Study , 2019, Pain and Therapy.
[30] A. Singla,et al. Su1928 – Tofacitinib Improves Clinical Disease Activity in a Real-World Population of Patients with Moderate-Severe Ulcerative Colitis and Crohn’s Disease , 2019, Gastroenterology.
[31] P. Higgins,et al. Efficacy of Induction Therapy With High‐Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[32] M. Dubinsky,et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. , 2019, Gastroenterology.
[33] D. Rubin,et al. Real-World Experience with Tofacitinib in IBD at a Tertiary Center , 2019, Digestive Diseases and Sciences.
[34] P. Higgins,et al. Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study , 2017, Alimentary pharmacology & therapeutics.
[35] H. Valdez,et al. Tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: long‐term safety and efficacy in an open‐label extension study , 2018, The British journal of dermatology.
[36] S. Feldman,et al. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis , 2018, Inflammatory bowel diseases.
[37] S. Vermeire,et al. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study , 2018, Journal of Crohn's & colitis.
[38] S. Vermeire,et al. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib , 2018, Inflammatory bowel diseases.
[39] Pamela R. Tsuruda,et al. Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy , 2017, Journal of Inflammation.
[40] Subrata Ghosh,et al. Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study , 2017, The American Journal of Gastroenterology.
[41] M. Honczarenko,et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2 , 2017 .
[42] K. Winthrop. The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.
[43] Yuka Kanno,et al. Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.
[44] S. Vermeire,et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials , 2017, Gut.
[45] D. Nguyen,et al. P469 Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjects. , 2017, Journal of Crohn's & colitis.
[46] S. Schreiber,et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial , 2017, The Lancet.
[47] G. Lichtenstein,et al. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease , 2017, The American Journal of Gastroenterology.
[48] Adam R. Johnson,et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity , 2016, Science Translational Medicine.
[49] S. Swan,et al. Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects , 2016, Clinical pharmacology in drug development.
[50] J. Colombel,et al. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management , 2016, Clinical and Translational Gastroenterology.
[51] Ashwin N. Ananthakrishnan,et al. Epidemiology and risk factors for IBD , 2015, Nature Reviews Gastroenterology &Hepatology.
[52] A. Ananthakrishnan. Environmental Risk Factors for Inflammatory Bowel Diseases: A Review , 2015, Digestive Diseases and Sciences.
[53] G. Kaplan. IBD: Global variations in environmental risk factors for IBD , 2014, Nature Reviews Gastroenterology &Hepatology.
[54] W. Sandborn,et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[55] Mark E Flanagan,et al. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.
[56] B. Strober,et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment , 2013, The British journal of dermatology.
[57] J. O’Shea,et al. Janus kinase inhibitors in autoimmune diseases , 2013, Annals of the rheumatic diseases.
[58] G. Kaplan,et al. Environment and the inflammatory bowel diseases. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[59] Steven M Holland,et al. JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.
[60] J. Casanova,et al. Inborn errors of human JAKs and STATs. , 2012, Immunity.
[61] R. Plenge,et al. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.
[62] L. Peyrin-Biroulet,et al. Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.
[63] Y. Chung,et al. Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers , 2008, Clinical Cancer Research.
[64] W. Sandborn,et al. Venous Thromboembolism in Inflammatory Bowel Disease , 2004, American Journal of Gastroenterology.
[65] J. Johnston,et al. Signaling by type I and II cytokine receptors: ten years after. , 2001, Current opinion in immunology.
[66] R. Schreiber,et al. Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.
[67] T. Shows,et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. , 1990, Oncogene.
[68] A. Wilks. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[69] S. Hanauer,et al. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[71] W. Sandborn,et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.
[72] R. Levine. JAK-mutant myeloproliferative neoplasms. , 2012, Current topics in microbiology and immunology.
[73] Mary Lyn Gaffield,et al. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) , 2011 .
[74] W. Leonard,et al. Jaks and STATs: biological implications. , 1998, Annual review of immunology.